ESE Survey on Aggressive Pituitary Tumours

On behalf of the ESE Taskforce on Aggressive Pituitary Tumours, we would like to remind you that you are invited to participate in a survey on the management of aggressive pituitary tumours/carcinomas.

There is no consensus on the treatment algorithm for these challenging tumours. Current management derives from experience gleaned from limited patient numbers with short duration of follow up. This Taskforce recognises the need to collect information on larger patient cohorts and specifically to gather experience with temozolomide, other chemotherapeutic drugs and peptide receptor radionuclide therapy.

We appreciate you sharing your valuable experience. By completing the short survey you will contribute to improving our patients’ care. After a thorough discussion we feel that such a retrospective anonymous survey does not require a specific ethic committee vote in each centre. After a thorough discussion we feel that such a retrospective anonymous survey does not require a specific ethic committee vote in each centre.

Please complete our survey by the deadline of 15 March 2016 using this link. For more information please visit the ESE website. The results will be presented at the 19th European Congress of Endocrinology in Lisbon in May 2017, and your contribution will be acknowledged. Thank you to those who have already taken part.

You may be contacted in the future regarding the information provided. We appreciate the time taken to help us, and we thank you on behalf of the ESE Special Interest Group on Aggressive Pituitary Tumors.*

*Gerald Raverot (France) (Chair), Pia Burman (Sweden), Ann McCormack (Australia), Stephan Petersenn (Germany), Vera Popovic-Brkic (Serbia), Jacqueline Trouillas (France)